1. Home
  2. IMMP vs SLND Comparison

IMMP vs SLND Comparison

Compare IMMP & SLND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$0.37

Market Cap

54.4M

Sector

Health Care

ML Signal

HOLD

Logo Southland Holdings Inc.

SLND

Southland Holdings Inc.

HOLD

Current Price

$0.84

Market Cap

64.0M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMMP
SLND
Founded
1987
1900
Country
Australia
United States
Employees
N/A
1800
Industry
Biotechnology: Pharmaceutical Preparations
Military/Government/Technical
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
54.4M
64.0M
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
IMMP
SLND
Price
$0.37
$0.84
Analyst Decision
Hold
Hold
Analyst Count
3
1
Target Price
$5.50
$4.00
AVG Volume (30 Days)
634.9K
77.7K
Earning Date
05-12-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$445.09
N/A
Revenue Next Year
N/A
$9.59
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.29
$0.65
52 Week High
$3.53
$5.34

Technical Indicators

Market Signals
Indicator
IMMP
SLND
Relative Strength Index (RSI) 39.28 33.78
Support Level $0.35 $0.65
Resistance Level $0.39 $1.46
Average True Range (ATR) 0.02 0.09
MACD 0.01 -0.03
Stochastic Oscillator 33.66 2.52

Price Performance

Historical Comparison
IMMP
SLND

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

About SLND Southland Holdings Inc.

Southland Holdings Inc is an infrastructure construction company in North America. The company's infrastructure projects range from water conveyance systems and tunnels to long-span bridges and vertical structures. The company operates in two distinct segments: Civil and Transportation. The civil segment operates throughout North America and specializes in services that include the design and construction of water pipelines, pump stations, lift stations, water and wastewater treatment plants, concrete and structural steel, outfall, and tunneling. The transportation segment operates throughout North America and specializes in services that include the design and construction of bridges, roadways, marine, dredging, ship terminals and piers, and specialty structures and facilities.

Share on Social Networks: